<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6948816\results\search\tropicalVirus\results.xml">
  <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
  <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
  <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
  <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : People and places : Geographical locations :"/>
  <result pre="age-specific immunity on the timing and burden of the next" exact="Zika" post="virus outbreak Impact of age-specific immunity on the timing"/>
  <result pre="age-specific immunity on the timing and burden of the next" exact="Zika" post="virus outbreak http://orcid.org/0000-0003-1039-6873CounotteMichel J.ConceptualizationFormal analysisInvestigationMethodologyProject administrationSoftwareVisualizationWriting – original draft12*AlthausChristian"/>
  <result pre="author and source are credited.pntd.0007978.pdf Abstract The 2015–2017 epidemics of" exact="Zika" post="virus (ZIKV) in the Americas caused widespread infection, followed"/>
  <result pre="by protective immunity. The timing and burden of the next" exact="Zika" post="virus outbreak remains unclear. We used an agent-based model"/>
  <result pre="Managua, Nicaragua. We also investigated the potential impact of a" exact="ZIKV" post="vaccine. Assuming lifelong immunity, the risk of a ZIKV"/>
  <result pre="a ZIKV vaccine. Assuming lifelong immunity, the risk of a" exact="ZIKV" post="outbreak will remain low until 2035 and rise above"/>
  <result pre="will be at highest risk of infection during the next" exact="ZIKV" post="outbreak, increasing the expected number of congenital abnormalities. ZIKV"/>
  <result pre="next ZIKV outbreak, increasing the expected number of congenital abnormalities." exact="ZIKV" post="vaccine development and licensure are urgent to attain the"/>
  <result pre="This urgency increases if immunity is not lifelong. Author summary" exact="Zika" post="virus (ZIKV) caused a major outbreak in the Americas"/>
  <result pre="long herd immunity can protect a population against a new" exact="ZIKV" post="outbreak. Data from Managua, Nicaragua showed an imbalance in"/>
  <result pre="from Managua, Nicaragua showed an imbalance in protective immunity after" exact="ZIKV" post="infection across different age-strata. We used this data to"/>
  <result pre="mathematical model to predict the future risk of a new" exact="ZIKV" post="outbreak and to evaluate the effect of loss of"/>
  <result pre="will be at highest risk of infection during the next" exact="ZIKV" post="outbreak, increasing the expected number of congenital abnormalities. We"/>
  <result pre="Source code for the model is available from: https://github.com/ZikaProject/SeroProject. Introduction" exact="Zika" post="virus (ZIKV) is a flavivirus, which is transmitted primarily"/>
  <result pre="African and Asian countries [1, 2]. Between 2007 and 2013," exact="ZIKV" post="caused large-scale epidemics in the populations of Micronesia [3],"/>
  <result pre="Micronesia [3], French Polynesia [4] and other Pacific islands [1]." exact="ZIKV" post="probably became established in Aedes aegypti mosquitoes in the"/>
  <result pre="International Concern (PHEIC) [7]. WHO stated, in September 2016, that" exact="ZIKV" post="in pregnancy was the most likely cause of the"/>
  <result pre="By the beginning of 2018, over 220,000 confirmed cases of" exact="ZIKV" post="infection had been reported from Latin America and the"/>
  <result pre="lack of early recurrence [13], as has been seen with" exact="ZIKV" post="[14]. The duration of protective immunity induced by ZIKV"/>
  <result pre="with ZIKV [14]. The duration of protective immunity induced by" exact="ZIKV" post="infection remains uncertain, since immunity to ZIKV infection was"/>
  <result pre="immunity induced by ZIKV infection remains uncertain, since immunity to" exact="ZIKV" post="infection was not studied extensively before the 2013 outbreaks."/>
  <result pre="studies in French Polynesia and Fiji found that levels of" exact="ZIKV" post="neutralizing antibodies decrease with time [15]. If the fall"/>
  <result pre="means that people become susceptible to infection again, population level" exact="ZIKV" post="immunity might be declining already. Even if protective immunity"/>
  <result pre="if protective immunity is lifelong, the risk of a new" exact="ZIKV" post="outbreak will rise as susceptible newborns replace older individuals,"/>
  <result pre="data from the 2013 epidemic in French Polynesia, estimated that" exact="ZIKV" post="outbreaks are unlikely to occur for 12 to 20"/>
  <result pre="than older people [14]. That effect will be amplified if" exact="ZIKV" post="attack rates are lower in children than adults. Assessing"/>
  <result pre="are lower in children than adults. Assessing the risk of" exact="ZIKV" post="infection in women of reproductive age is essential because"/>
  <result pre="ZIKV infection in women of reproductive age is essential because" exact="ZIKV" post="infection in pregnancy, leading to adverse congenital outcomes, has"/>
  <result pre="is currently available against ZIKV. Phase I clinical trials of" exact="ZIKV" post="candidate vaccines have shown levels of neutralizing antibody titers"/>
  <result pre="Nicaragua were the first to report the age-stratified seroprevalence of" exact="ZIKV" post="antibodies in population-based surveys [23]. The first cases of"/>
  <result pre="antibodies in population-based surveys [23]. The first cases of autochthonous" exact="ZIKV" post="infection in Nicaragua were reported in January, 2016, and"/>
  <result pre="authorities of Nicaragua reported a total of 2,795 people with" exact="ZIKV" post="detected by reverse transcriptase (RT) PCR over this period"/>
  <result pre="symptomatic infections is likely much higher, owing to under-reporting. Furthermore," exact="ZIKV" post="infection is asymptomatic in 33 to 87% of cases"/>
  <result pre="in Managua to measure the prevalence of IgG antibodies against" exact="ZIKV" post="in 2- to 14-year olds (N = 3,740) and"/>
  <result pre="to 80-year olds (N = 2,147) [23]. The authors reported" exact="ZIKV" post="seroprevalence of 36.1% (95% confidence interval, CI: 34.5; 37.8%)"/>
  <result pre="In this study, we used published data from the 2016" exact="ZIKV" post="epidemic in Managua and developed an agent-based model (ABM)"/>
  <result pre="(ABM) to predict the evolution of age-specific protective immunity to" exact="ZIKV" post="infection in the population of Managua, Nicaragua during the"/>
  <result pre="period 2017–2097. We assessed: 1) the risk of a future" exact="ZIKV" post="outbreak; 2) the consequences of a future ZIKV outbreak"/>
  <result pre="a future ZIKV outbreak; 2) the consequences of a future" exact="ZIKV" post="outbreak on women of reproductive age; 3) the influence"/>
  <result pre="future attack rates; and 4) how vaccination could prevent future" exact="ZIKV" post="outbreaks. Materials and methods Modelling strategy We assessed the"/>
  <result pre="Modelling strategy We assessed the consequences of future outbreaks of" exact="ZIKV" post="infection in Managua, Nicaragua using a stochastic ABM. The"/>
  <result pre="a basic susceptible-infected-recovered (SIR) framework and integrates processes related to" exact="ZIKV" post="transmission, immunity, demography, adverse congenital outcomes and vaccination (Table"/>
  <result pre="on published estimates or inferences from data about the 2016" exact="ZIKV" post="epidemic (Table 1, Supporting information S1). We considered different"/>
  <result pre="about the duration of immunity, the timing and scale of" exact="ZIKV" post="reintroductions in the population, and the timing and scale"/>
  <result pre="10.1371/journal.pntd.0007978.t001Table 1 Parameterization of the agent-based model. Parameter Comment Source" exact="ZIKV" post="epidemic parameters  Transmission ratea Inferred from the 2016 epidemicb"/>
  <result pre="epidemicb [23]  Recovery rate Inferred from the 2016 epidemicb [23]" exact="ZIKV" post="immunity  Initial immunitya Inferred from the 2016 epidemicb [23]"/>
  <result pre="ratea – [29]  Ageing Linear ageing at each time-step –" exact="ZIKV" post="reintroduction  Delay until reintroduction 1 to 80 years 80"/>
  <result pre="individuals for 80 years (2017–2097). We assigned agents’ age and" exact="ZIKV" post="infection status (susceptible S, infected I or immune R)."/>
  <result pre="The model code and data are available from http://github.com/ZikaProject/SeroProject. Parameterization" exact="ZIKV" post="epidemic parameters We inferred the probability distributions for the"/>
  <result pre="and the recovery rate γ from data on the 2016" exact="ZIKV" post="epidemic in Managua, Nicaragua. We used surveillance data [23],"/>
  <result pre="used surveillance data [23], which give weekly numbers of incident" exact="ZIKV" post="infections, confirmed by RT-PCR (dataset A, n = 1,165),"/>
  <result pre="(dataset A, n = 1,165), and survey data on age-stratified" exact="ZIKV" post="seroprevalence, measured among participants of pediatric and household cohort"/>
  <result pre="short time span. We recorded the overall cumulative incidence of" exact="ZIKV" post="cases using a dummy compartment: d C d t"/>
  <result pre="estimates inferred from incidence and sero-prevalence data on the 2016" exact="ZIKV" post="epidemic in Managua, Nicaragua. Parameter Interpretation Prior Posterior (median"/>
  <result pre="Basic reproduction number – 1.58 (1.56; 1.59) CrI: Credible interval." exact="ZIKV" post="immunity We used the deterministic model, described in the"/>
  <result pre="ABM to allow the propagation of uncertainty. Protective immunity to" exact="ZIKV" post="after infection was lifelong in our first scenario, so"/>
  <result pre="each agent by 7 days at each 7-day time step." exact="ZIKV" post="reintroduction We reintroduced ZIKV in the population after a"/>
  <result pre="days at each 7-day time step. ZIKV reintroduction We reintroduced" exact="ZIKV" post="in the population after a delay of d ="/>
  <result pre="an extinction of the outbreak depends on the number of" exact="ZIKV" post="cases reintroduced in the population, we considered three different"/>
  <result pre="estimated number of microcephaly cases resulting from the reintroduction of" exact="ZIKV" post="depended on the exposure, i.e. the number of pregnant"/>
  <result pre="the exposure, i.e. the number of pregnant women infected by" exact="ZIKV" post="during their first trimester, to which we applied three"/>
  <result pre="on published estimates [10, 11]. We obtained the number of" exact="ZIKV" post="infections among women aged 15–49 years from ABM simulations."/>
  <result pre="of risk of microcephaly in births to pregnant woman with" exact="ZIKV" post="infection during the first trimester, as reported by Zhang"/>
  <result pre="10, 11]. Vaccination We examined the effects of a potential" exact="ZIKV" post="vaccine, given to 15-year-old-girls. This vaccination strategy was used"/>
  <result pre="the simulations, we collected 1) the evolution of the age-specific" exact="ZIKV" post="immunity in the population; 2) the attack rate resulting"/>
  <result pre="population; 2) the attack rate resulting from the reintroduction of" exact="ZIKV" post="at year d; 3) the age of newly infected"/>
  <result pre="vector density, of migration, and of an endemic circulation of" exact="ZIKV" post="on our predictions regarding the attack rate and the"/>
  <result pre="and assumptions are provided in Supporting information S2. Results 2016" exact="ZIKV" post="epidemic The fitted model (Fig 1), resulted in a"/>
  <result pre="≥15 age group. Fig 1 Model fit for the 2016" exact="ZIKV" post="epidemic. Model fit for (A) weekly incidence data and"/>
  <result pre="incidence data and (B) post-epidemic sero-prevalence data from the 2016" exact="ZIKV" post="epidemic in Managua, Nicaragua. Data points are in red"/>
  <result pre="by 42% between 2017 and 2097. Under the assumption that" exact="ZIKV" post="infection results in lifelong protective immunity, population renewal will"/>
  <result pre="old age group by 2046. Fig 2 Future risk of" exact="ZIKV" post="outbreaks. (A) The evolution of the immunity status per"/>
  <result pre="distribution of the attack rates resulting from the reintroduction of" exact="ZIKV" post="in the population at each year (1000 simulations for"/>
  <result pre="and effective reproduction number R e (purple). Future risk of" exact="ZIKV" post="outbreak Reintroductions of ZIKV in the population of Managua"/>
  <result pre="R e (purple). Future risk of ZIKV outbreak Reintroductions of" exact="ZIKV" post="in the population of Managua are unlikely to develop"/>
  <result pre="2016 (Fig 2B). After this point, attack rates resulting from" exact="ZIKV" post="reintroduction will rise steeply. By 2047, we predict that"/>
  <result pre="ZIKV reintroduction will rise steeply. By 2047, we predict that" exact="ZIKV" post="reintroductions will have a 50% probability of resulting in"/>
  <result pre="that the number of adverse congenital outcomes resulting from a" exact="ZIKV" post="outbreak during this period is likely to be higher"/>
  <result pre="different values for the added risk of microcephaly after a" exact="ZIKV" post="infection during the first trimester, we expect the mean"/>
  <result pre="expect the mean number of additional microcephaly cases due to" exact="ZIKV" post="infection resulting from the reintroduction of the virus in"/>
  <result pre="births in women of reproductive age. (A) Relative risk of" exact="ZIKV" post="infection during a ZIKV outbreak per age group compared"/>
  <result pre="reproductive age. (A) Relative risk of ZIKV infection during a" exact="ZIKV" post="outbreak per age group compared to the general population"/>
  <result pre="range). (B) Expected number of additional microcephaly events associated with" exact="ZIKV" post="infection during pregnancy per 100,000 total population according to"/>
  <result pre="different risk scenarios. Loss of immunity If protective immunity to" exact="ZIKV" post="is not lifelong, the time window before observing a"/>
  <result pre="before observing a rise in the attack rates resulting from" exact="ZIKV" post="reintroduction will shorten (Fig 4A). For instance, if 15%"/>
  <result pre="lifelong immunity (thick black line): (A) median attack rate of" exact="ZIKV" post="among reintroductions resulting in outbreaks (with a threshold of"/>
  <result pre="(with a threshold of 1%) and (B) relative risk of" exact="ZIKV" post="infection during an outbreak in the 15–29 year age"/>
  <result pre="and would also indirectly reduce the overall risk of a" exact="ZIKV" post="outbreak in the population (Fig 5). If effective vaccine"/>
  <result pre="herd immunity could effectively mitigate the overall risk of a" exact="ZIKV" post="outbreak in the population. The reduction in the number"/>
  <result pre="with no vaccination (thick black line). (A) relative risk of" exact="ZIKV" post="infection during an outbreak in the 15–29 year age"/>
  <result pre="compared with the general population and (B) attack rate of" exact="ZIKV" post="among reintroductions resulting in outbreaks (median, interquartile range, with"/>
  <result pre="shorter time window until a rise in the risk of" exact="ZIKV" post="outbreak, and higher overall attack rates. A future diminution"/>
  <result pre="the population, also lowering the time window before the next" exact="ZIKV" post="outbreak. Finally, a continuous endemic circulation of ZIKV in"/>
  <result pre="the next ZIKV outbreak. Finally, a continuous endemic circulation of" exact="ZIKV" post="in the region would increase the probability of an"/>
  <result pre="In this mathematical modelling study, we show that a new" exact="ZIKV" post="outbreak in Nicaragua would affect proportionally more women in"/>
  <result pre="infection pattern and population renewal. The risk of a new" exact="ZIKV" post="outbreak in Nicaragua, after reintroduction, will remain low before"/>
  <result pre="then rise to 50% in 2047. If protective immunity to" exact="ZIKV" post="decays with time, ZIKV recurrence could occur sooner. Timely"/>
  <result pre="in 2047. If protective immunity to ZIKV decays with time," exact="ZIKV" post="recurrence could occur sooner. Timely introduction of targeted vaccination,"/>
  <result pre="which is crucial when studying adverse congenital events caused by" exact="ZIKV" post="infection during pregnancy. We chose a simple approach based"/>
  <result pre="the human population. We acknowledge that the future occurrence of" exact="ZIKV" post="in the area also depends on the presence of"/>
  <result pre="superior to a simple SIR structure in describing the 2016" exact="ZIKV" post="epidemic of Managua (Supporting information S1). Similarly, Pandey et"/>
  <result pre="studies This study shows that the lower attack rate of" exact="ZIKV" post="in children than in adults will hasten the emergence"/>
  <result pre="the processes of ageing in relation to protective immunity to" exact="ZIKV" post="explicitly. Even with lifelong immunity, our model predicts that"/>
  <result pre="year olds, including women who will be at risk of" exact="ZIKV" post="infection in pregnancy. If immunity wanes, the time until"/>
  <result pre="in pregnancy. If immunity wanes, the time until the next" exact="ZIKV" post="outbreak will be reduced and, in that case, the"/>
  <result pre="4). Several authors have studied the time to a next" exact="ZIKV" post="outbreak, but none studied the effect of the loss"/>
  <result pre="et al. (2016) concluded that the age distribution of future" exact="ZIKV" post="outbreaks will likely differ and that a new large"/>
  <result pre="will be delayed for &quot;at least a decade�? [14]. Other" exact="ZIKV" post="vaccination studies confirm our findings. However, they do not"/>
  <result pre="[42]. Valega-Mackenzie et al. (2018) formulated a vaccination model for" exact="ZIKV" post="transmission that included mosquito and sexual transmission [43]. They"/>
  <result pre="we expect a higher number of congenital abnormalities due to" exact="ZIKV" post="infection. Thus, vaccine development efforts should be increased. Our"/>
  <result pre="documented high post-epidemic levels of seropositivity [25–27]. In regions where" exact="ZIKV" post="has not yet caused an epidemic but competent vectors"/>
  <result pre="with longitudinal follow-up, are needed to improve our understanding of" exact="ZIKV" post="antibody distribution in populations and to quantify the duration"/>
  <result pre="information will provide important information to improve mathematical modeling of" exact="ZIKV" post="risk. ZIKV vaccine development faces considerable hurdles. First, the"/>
  <result pre="provide important information to improve mathematical modeling of ZIKV risk." exact="ZIKV" post="vaccine development faces considerable hurdles. First, the evaluation of"/>
  <result pre="of vaccine efficacy has stalled because the reduced circulation of" exact="ZIKV" post="has reduced the visibility of ZIKV-associated disease [22]. Second,"/>
  <result pre="it is not clear whether or how vaccine-induced antibodies against" exact="ZIKV" post="will cross-react with other flaviviruses. To move vaccine development"/>
  <result pre="and implementing surveillance there. These can either be regions where" exact="ZIKV" post="is endemic, or where ZIKV outbreaks are likely to"/>
  <result pre="can either be regions where ZIKV is endemic, or where" exact="ZIKV" post="outbreaks are likely to occur; throughout the Americas, there"/>
  <result pre="is complex, but there are tools to facilitate planning [45]." exact="ZIKV" post="in an endemic setting, such as in Africa and"/>
  <result pre="and Asia, could prove a suitable setting as well. However," exact="ZIKV" post="circulation in endemic setting is not well described and"/>
  <result pre="gives us the opportunity to be prepared. The next sizeable" exact="ZIKV" post="outbreak in Nicaragua will likely not occur before 2035"/>
  <result pre="will be at highest risk of infection during the next" exact="ZIKV" post="outbreak. Vaccination targeted to young women could curb the"/>
  <result pre="the risk of a large outbreak and extend herd immunity." exact="ZIKV" post="vaccine development and licensure are urgent to attain the"/>
  <result pre="and the risk of adverse congenital outcomes. The urgency of" exact="ZIKV" post="vaccine development increases if immunity is not lifelong. Supporting"/>
  <result pre="cluster at the University of Bern. References References 1WikanN, SmithDR." exact="Zika" post="virus: History of a newly emerging arbovirus. Lancet Infect"/>
  <result pre="newly emerging arbovirus. Lancet Infect Dis. 2016;16(7):e119–e126. 10.1016/S1473-3099(16)30010-X27282424 2KohlA, GathererD." exact="Zika" post="virus: a previously slow pandemic spreads rapidly through the"/>
  <result pre="SunK, ChinazziM, Pastore Y PionttiA, DeanNE, RojasDP, et al.Spread of" exact="Zika" post="virus in the Americas. Proc Natl Acad Sci U"/>
  <result pre="the International Health Regulations (2005) (IHR 2005) Emergency Committee on" exact="Zika" post="virus and observed increase in neurological disorders and neonatal"/>
  <result pre="2018;7(196):19610.12688/f1000research.13704.130631437 10CauchemezS, BesnardM, BompardP, DubT, Guillemette-ArturP, Eyrolle-GuignotD, et al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013-15: A retrospective"/>
  <result pre="retrospective study. Lancet. 2016;387(10033):2125–2132. 10.1016/S0140-6736(16)00651-626993883 11JohanssonMA, Mier-Y-Teran-RomeroL, ReefhuisJ, GilboaSM, HillsSL." exact="Zika" post="and the risk of Microcephaly. Obstet Gynecol Surv. 2016;71(11):635–636."/>
  <result pre="1975;104:104–121. 14FergusonNM, CucunubáZM, DorigattiI, Nedjati-GilaniGL, DonnellyCA, BasáñezMG, et al.Countering the" exact="Zika" post="epidemic in Latin America. Science. 2016;353(6297):353–354. 10.1126/science.aag021927417493 15HendersonAD, AubryM,"/>
  <result pre="578211. 16KucharskiAJ, FunkS, EggoRM, MalletHP, EdmundsWJ, NillesEJ. Transmission Dynamics of" exact="Zika" post="Virus in Island Populations: A Modelling Analysis of the"/>
  <result pre="Polynesia Outbreak. PLoS Negl Trop Dis. 2016;10(5):e000472610.1371/journal.pntd.000472627186984 17AbbinkP, StephensonKE, BarouchDH." exact="Zika" post="virus vaccines. Nat Rev Microbiol. 2018;16(10):594–600. 10.1038/s41579-018-0039-729921914 18World Health"/>
  <result pre="HuZ, YamshchikovG, RothwellRS, et al.Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
  <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
  <result pre="21National Institute of Allergy and Infectious Diseases. VRC 705: A" exact="Zika" post="Virus DNA Vaccine in Healthy Adults and Adolescents (DNA);"/>
  <result pre="(DNA); 2018. [Online]. Available from: https://clinicaltrials.gov/ct2/show/NCT03110770. 22CohenJ. Steep drop in" exact="Zika" post="cases undermines vaccine trial. Science. 2018;361(6407):1055–1056. 10.1126/science.361.6407.105530213891 23ZambranaJV, Bustos"/>
  <result pre="SanchezN, OjedaS, et al.Seroprevalence, risk factor, and spatial analyses of" exact="Zika" post="virus infection after the 2016 epidemic in Managua, Nicaragua."/>
  <result pre="24BalmasedaA, StettlerK, Medialdea-CarreraR, ColladoD, JinX, ZambranaJV, et al.Antibody-based assay discriminates" exact="Zika" post="virus infection from other flaviviruses. Proc Natl Acad Sci."/>
  <result pre="2017;23(10):1751–1753. 10.3201/eid2310.17058328930020 26NettoEM, Moreira-SotoA, PedrosoC, HöserC, FunkS, KucharskiAJ, et al.High" exact="Zika" post="Virus Seroprevalence in Salvador, Northeastern Brazil Limits the Potential"/>
  <result pre="in the variability of the basic reproductive number (R0) for" exact="Zika" post="epidemics in the Pacific islands. Elife. 2016;510.7554/eLife.1987427897973 38PandeyA, MubayiA,"/>
  <result pre="FariaNR, WalkerA, KraemerMUG, Villabona-ArenasCJ, et al.Epidemiological and ecological determinants of" exact="Zika" post="virus transmission in an urban setting. Elife. 2017;610.7554/eLife.2982028887877 41DurhamDP,"/>
  <result pre="DurhamDP, RandallS, HotezPJ, et al.What Is the Value of Different" exact="Zika" post="Vaccination Strategies to Prevent and Mitigate Zika Outbreaks?J Infect"/>
  <result pre="Value of Different Zika Vaccination Strategies to Prevent and Mitigate" exact="Zika" post="Outbreaks?J Infect Dis. 2018. 43Valega-MackenzieW, Ríos-SotoKR. Can Vaccination Save"/>
  <result pre="Outbreaks?J Infect Dis. 2018. 43Valega-MackenzieW, Ríos-SotoKR. Can Vaccination Save a" exact="Zika" post="Virus Epidemic?Bull Math Biol. 2018;80(3):598–625. 10.1007/s11538-018-0393-729359251 44DiamondMS, LedgerwoodJE, PiersonTC."/>
  <result pre="Zika Virus Epidemic?Bull Math Biol. 2018;80(3):598–625. 10.1007/s11538-018-0393-729359251 44DiamondMS, LedgerwoodJE, PiersonTC." exact="Zika" post="Virus Vaccine Development: Progress in the Face of New"/>
 </snippets>
</snippetsTree>
